Other substances

LNP-nCoVsaRNA

COVID-19 candidate vaccine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

LNP-nCoVsaRNA is a COVID-19 candidate vaccine being developed by Imperial College London. It is an saRNA type of candidate vaccine. It is based on the RNA platform, which is also used for non-COVID-19 candidates, such as EBOV, LASV, MARV, Inf (H7N9), and RABV. Currently, this COVID-19 candidate vaccine is in Phase I clinical trial.

 

Supporting references

Link Tested on Impact factor Notes Publication date
DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020
in vitro Mar/26/2020

AI-suggested references

Link Publication date
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
Jan/14/2022
Export (.csv)